Anti-CD39 Antibody CDR Optimization for Cancer Cell Growth Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing anti-CD39 antibodies do not exhibit sufficiently strong cancer cell growth inhibitory effects.

Innovation Solution

Development of anti-CD39 antibodies with specific heavy and light chain CDR sequences (SEQ ID NOs: 1-42) that demonstrate enhanced cancer cell growth inhibitory effects, immune cell cytotoxicity, and TNFα production.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional anti-CD39 antibodies are used, then CD39 binding capability is achieved, but cancer cell growth inhibitory effects are insufficient

Engineering Contradiction:

Improvecancer cell growth inhibitory effectsVSAvoidinsufficient cancer cell growth inhibition

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies parameter changes by modifying the CDR sequences of the antibody to achieve superior binding affinity and functional activity. Specifically, the heavy chain CDR1, CDR2, and CDR3 sequences along with light chain CDR1, CDR2, and CDR3 sequences are optimized to enhance the antibody's ability to inhibit CD39 enzyme activity and suppress cancer cell growth, directly resolving the contradiction between conventional antibody binding capability and sufficient cancer cell growth inhibition.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If existing anti-CD39 antibodies are used, then CD39 enzyme activity inhibition is achieved, but immune cell cytotoxicity promotion is insufficient

Engineering Contradiction:

Improveimmune cell cytotoxicity promotionVSAvoidinsufficient immune cell cytotoxicity

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent optimizes the CDR sequences to enhance the antibody's ability to promote immune cell cytotoxicity. The specific amino acid sequences in heavy chain CDR1 (SEQ ID NO: 1, 7, 13, 19, 25, 31, or 37), CDR2 (SEQ ID NO: 2, 8, 14, 20, 26, 32, or 38), and CDR3 (SEQ ID NO: 3, 9, 15, 21, 27, 33, or 39), along with light chain CDR sequences, are designed to strengthen the antibody's capacity to activate immune cells and enhance their cytotoxic effect against cancer cells.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If existing anti-CD39 antibodies are used, then CD39 binding is achieved, but TNFα production enhancement is insufficient

Engineering Contradiction:

ImproveTNFα production enhancementVSAvoidinsufficient TNFα production

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent modifies the CDR sequences to enhance TNFα production by immune cells. The optimized heavy chain CDR sequences (SEQ ID NO: 1-39) and light chain CDR sequences (SEQ ID NO: 4-42) create binding interfaces that specifically stimulate TNFα secretion from immune cells, thereby resolving the contradiction between conventional antibody binding and TNFα production enhancement.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250215105A1Anti-CD39 antibody

Publication Date: 2025.07.03 BRIGHTPATH BIOTHERAPEUTICS CO LTD

AI summary

The present invention addresses the problem of obtaining a superior anti-CD39 antibody. Provided is an antibody or antigen-binding fragment capable of binding to CD39, comprising heavy chain CDRs 1-3 and light chain CDRs 1-3 each containing a specific amino acid sequence. This antibody may be a CD39-neutralizing antibody. This antibody may have an ability to inhibit the growth of malignant tumor.